BrioHealth Technologies

Our company

CH Biomedical, Inc.(CHB) was founded in 2008 by a team of scientific and technological experts with overseas experience with the goal of bringing improved survival and quality of life to end-stage heart failure patients. The headquarters of CH Biomedical is located in Suzhou Industrial Park, while the wholly-owned subsidiary, CH Biomedical USA, Inc., is in LA, California. CH Biomedical focuses on the research and development of the world’s state-of-the art ventricular assist device (VAD), promotes the commercialization of the VADs, and brings benefits to patients with end-stage heart failure.

Ventricular assist device (VAD) represents the scientific and technological level of a country's high-end medical devices. It integrates many cutting-edge technologies and advanced sciences in the fields of biomedical engineering such as mechanical design, software control, integrated circuit, and fluid dynamics, as well as experience in the development, management, and manufacturing of high-end medical devices. After more than 10 years of independent research and development in the field of VAD, Our company has developed a new generation of LVAD CH-VAD^® with full magnetic levitation technology, and continues to show its strength as a global technology leader in this emerging segment. CHB has completed its initial clinical trial in China. Plans are underway to expand global access to CHB’s lifesaving technology and next-generation maglev CH-VAD^® in the United States and other countries.

Adhering to the core values of “Integrity, Truth, Respect, Excellence”, CHB is committed to leading the global artificial heart technology advancement and service improvement, so that more patients with advanced heart failure and their families can enjoy a healthy and happy life again.

Vision

To become a global leading science and technology company in advancement of VAD research and development.
Mission

To enable more patients with heart failure and their families to enjoy a healthy and happy life again.

Milestones

Jul. | CH Biomedical, Inc. was founded in Suzhou Industrial Park.
Oct. | Awarded as one of the “Leading Talents of Science and Technology in Suzhou Industrial Park”.

Jun. | The US subsidiary was officially founded.
Sep. | Prototype X1 was successfully developed.
Nov. | Selected for the National High-tech R&D Program (863 Program) under the "11th Five-Year Plan".

Jan. | Awarded as one of the Gusu Leading Talent Projects by Suzhou Science and Technology Bureau.
May | Selected for the Science and Technology Surport Program funded by Jiangsu Provincial Department of Science and Technology.

Oct. | X2 prototype was finalized, and the animal study was conducted.

Mar. | Selected for the National High-tech R&D Program (863 Program) under the 12th Five-Year Plan.
Apr. | X3 prototype was successfully developed.
Dec. | X4 prototype was finalized.

Jan. | R&D of the X5 prototype launched.

Dec. | The X5 bump design was finalized, and the preclinical animal experiments were successfully completed.

Oct. | CH-VAD Left Ventricular Assist System was officially finalized.

Jun. | CH-VAD received Fast Track Designation from NMPA for Investigational Medical Devices application.

Jun. | The first in human (FIH) implantation of CH-VAD was successfully performed, making the successful clinical application of the new medical technology.
Jul. | Selected for the National Key R&D Program under the 13th Five-Year Plan.

Nov. | The company was invited for the first time to present its product at the 26th Annual Meeting of the International Society for Mechanical Circulatory Support (ISMCS).
Dec. | The company received clinical trial approval from the National Medical Products Administration (NMPA).

Mar. | Clinical trials officially started in China.
Apr. | A research article titled “Evaluation of in vitro hemolysis and platelet activation of a newly developed maglev LVAD and two clinically used LVADs with human blood”was published in Artificial Organs (Sep 2019;43(9):870-879. doi: 10.1111/aor.13471).

Nov. | The research article titled “Computational characterization of flow and blood damage potential of the new maglev CH-VAD pump versus the HVAD and HeartMate II pumps” was published in Artificial Organs (Oct 2020; 43(10):653-662).

Mar. | Successfully passed the Good Manufacturing Practice (GMP) inspection by the National Medical Products Administration (NMPA).
Nov. | CH-VAD was officially approved for marketing by the NMPA (Registration No.: GXZZ 20213120987).

Apr. | CH-VAD was selected as one of the “Important Medical Advancements in China in 2021”‌‌.
Jun. | First commercial implantation of CH-VAD successfully completed.

Apr. | CH-VAD was recognized as one of the “Major Medical Achievements of 21st Century China”.

Apr. | The Investigational Device Exemption (IDE) application for the BrioVAD system was approved by the U.S. FDA.
May | Long-term clinical outcomes of CH-VAD were published in The Journal of Heart and Lung Transplantation.
Nov. | Awarded First Prize of the 2023 Jiangsu Science and Technology Award.
Nov. | First patient enrolled in the U.S. clinical trial of the BrioVAD system.

Jan. | Awarded First Prize of the 2024 Chinese Medical Science and Technology Award.

About Us

Our company

Vision

Mission

OUR FOUNDERS

Milestones